GSK Admits Voltaren Marketing Misled Australian Consumers,Now Facing Financial Penalty

摘要

Australia’s Federal Court has accepted an admission by GlaxoSmith-Kline PLC that it,along with former joint venture partner Novartis AG,misled consumers and broke consumer law by promoting identical products to treat different types of pain.The firms had engaged in”a deliberate and considered marketing strategy”from January 2012 to March 2017,the court said,by promoting Voltaren Osteo Gel on product packaging and online as being specifically formulated and more effective than Voltaren Emulgel in treating – pain and inflammation.The active ingredient in both products is diclofenac diethylammonium,at an identical dose level of 11.6mg/g.